These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

182 related articles for article (PubMed ID: 18500470)

  • 21. A comparison of the cost-effectiveness of five strategies for the prevention of non-steroidal anti-inflammatory drug-induced gastrointestinal toxicity: a systematic review with economic modelling.
    Brown TJ; Hooper L; Elliott RA; Payne K; Webb R; Roberts C; Rostom A; Symmons D
    Health Technol Assess; 2006 Oct; 10(38):iii-iv, xi-xiii, 1-183. PubMed ID: 17018227
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Efficacy of the newest COX-2 selective inhibitors in rheumatic disease.
    Baraf HS
    Curr Pharm Des; 2007; 13(22):2228-36. PubMed ID: 17691996
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Nonsteroidal anti-inflammatory drugs and cardiovascular risk - a matter of indication.
    Braun J; Baraliakos X; Westhoff T
    Semin Arthritis Rheum; 2020 Apr; 50(2):285-288. PubMed ID: 31439354
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Cyclooxygenase-2 inhibitors, nonsteroidal anti-inflammatory drugs, and cardiovascular risk.
    Vardeny O; Solomon SD
    Cardiol Clin; 2008 Nov; 26(4):589-601. PubMed ID: 18929233
    [TBL] [Abstract][Full Text] [Related]  

  • 25. NSAIDs in ankylosing spondylitis.
    Miceli-Richard C; Dougados M
    Clin Exp Rheumatol; 2002; 20(6 Suppl 28):S65-6. PubMed ID: 12463450
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Cardiovascular outcomes in new users of coxibs and nonsteroidal antiinflammatory drugs: high-risk subgroups and time course of risk.
    Solomon DH; Avorn J; Stürmer T; Glynn RJ; Mogun H; Schneeweiss S
    Arthritis Rheum; 2006 May; 54(5):1378-89. PubMed ID: 16645966
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Non-steroidal anti-inflammatory drugs in patients with stable ankylosing spondylitis receiving tumor necrosis factor inhibitor: continued vs withdrawn.
    Park JH; Kwon OC; Park MC
    Clin Rheumatol; 2020 Dec; 39(12):3669-3675. PubMed ID: 32447601
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Bechterew disease--a consensus on diagnosis and treatment].
    Dagfinrud H; Heiberg MS; Bakland G; Skomsvoll J; Kvien TK
    Tidsskr Nor Laegeforen; 2007 Dec; 127(24):3209-12. PubMed ID: 18084362
    [TBL] [Abstract][Full Text] [Related]  

  • 29. New directions in symptomatic therapy for patients with osteoarthritis and rheumatoid arthritis.
    Hochberg MC
    Semin Arthritis Rheum; 2002 Dec; 32(3 Suppl 1):4-14. PubMed ID: 12528069
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Non-Steroidal anti inflammatory drugs usage in orthopaedics and trauma practice. A guide and review.
    Eyichukwu GO
    Niger J Med; 2010; 19(4):374-81. PubMed ID: 21526623
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Safety of non-steroidal anti-inflammatory drugs, including aspirin and paracetamol (acetaminophen) in people receiving methotrexate for inflammatory arthritis (rheumatoid arthritis, ankylosing spondylitis, psoriatic arthritis, other spondyloarthritis).
    Colebatch AN; Marks JL; Edwards CJ
    Cochrane Database Syst Rev; 2011 Nov; (11):CD008872. PubMed ID: 22071858
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Cardiovascular effects of coxibs.
    Caporali R; Montecucco C
    Lupus; 2005; 14(9):785-8. PubMed ID: 16218488
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Cost effectiveness of etoricoxib versus celecoxib and non-selective NSAIDS in the treatment of ankylosing spondylitis.
    Jansen JP; Gaugris S; Choy EH; Ostor A; Nash JT; Stam W
    Pharmacoeconomics; 2010; 28(4):323-44. PubMed ID: 20222755
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Use of gastroprotective agents and discontinuations due to dyspepsia with the selective cyclooxygenase-2 inhibitor etoricoxib compared with non-selective NSAIDs.
    Watson DJ; Bolognese JA; Yu C; Krupa D; Curtis S
    Curr Med Res Opin; 2004 Dec; 20(12):1899-908. PubMed ID: 15701208
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Tolerance to coxibs in patients with intolerance to non-steroidal anti-inflammatory drugs (NSAIDs): a systematic structured review of the literature.
    Weberschock TB; Müller SM; Boehncke S; Boehncke WH
    Arch Dermatol Res; 2007 Jul; 299(4):169-75. PubMed ID: 17492455
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Ankylosing spondylitis and symptom-modifying vs disease-modifying therapy.
    Akkoc N; van der Linden S; Khan MA
    Best Pract Res Clin Rheumatol; 2006 Jun; 20(3):539-57. PubMed ID: 16777581
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Etoricoxib in ankylosing spondylitis: is there a role for active patients refractory to traditional NSAIDs?
    Gratacós J; Moreno Martínez-Losa M; Font P; Montilla C; Fernández-Espartero C; Linares LF; Brito E; Oliva JC; Collantes-Estevez E;
    Clin Exp Rheumatol; 2016; 34(1):94-9. PubMed ID: 26812050
    [TBL] [Abstract][Full Text] [Related]  

  • 38. COXIBs, CINODs and H₂S-releasing NSAIDs: current perspectives in the development of safer non steroidal anti-inflammatory drugs.
    Fiorucci S; Distrutti E
    Curr Med Chem; 2011; 18(23):3494-505. PubMed ID: 21756233
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Coxibs, Traditional NSAIDs, and Cardiovascular Safety Post-PRECISION: What We Thought We Knew Then and What We Think We Know Now.
    Patrono C; Baigent C
    Clin Pharmacol Ther; 2017 Aug; 102(2):238-245. PubMed ID: 28378879
    [TBL] [Abstract][Full Text] [Related]  

  • 40. COX-2 inhibitors and the heart: are all coxibs the same?
    Sooriakumaran P
    Postgrad Med J; 2006 Apr; 82(966):242-5. PubMed ID: 16597810
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.